

Roberto Gomeni, PhD, Marina Komolova, PhD,† Bev Incledon, PhD,‡ and Stephen V. Faraone, PhD§*

HLD200 is a once-daily, evening-dosed, delayed-release and extended-release formulation of MPH (DR/ER-MPH; JORNAY PM; Ironshore Pharmaceuticals Inc, Durham, North Carolina). Using DELEXIS drug delivery technology, microbeads consisting of an MPH-loaded core are surrounded by 2 functional film layers that function synergistically to provide a prolonged delay in drug release after ingestion and subsequent extended release in the colon. In PK studies, evening administration of DR/ER-MPH produced a monophasic PK profile characterized by an 8- to

DOI: 10.1097/JCP.0000000000001222

10-hour delay in initial MPH release, followed by a period of extended, controlled release, resulting in an ascending absorption profile that coincided with the early morning and afternoon and, because of its targeting to the less absorptive colon, a protracted absorption window later in the day.²⁰ Moreover, studies showed that the weight-adjusted PK profiles of DR/ER-MPH were similar between healthy adults and children and adolescents with ADHD.²⁰ In 2 phase 3 trials, DR/ER-MPH demonstrated significant improvements in ADHD symptom control throughout the day, impaired classroom-observed behaviors, and functional impairment during the early morning and late afternoon/evening outside the classroom environment.^{21,22}

Model-based approaches are increasingly being used in drug development, in clinical trial design, and for regulatory and therapeutic decisions to predict the time course of drug exposure and clinical response, identify variables that affect efficacy and safety, and optimize or individualize treatment in patients.^{13,23} Given the plethora of MPH formulations already available and additional investigational products currently in development, it is critical to define and implement a rational modeling framework that accurately evaluates the drug release characteristics and distinct PK profiles of different formulations in relation to an optimal clinical response.^{12,13,24} By applying such model-based approaches, more well-informed and cost-effective decisions can be made to ensure that existing drugs are used appropriately to individualize therapy and that novel formulations are developed to target unmet needs and treatment gaps in ADHD.

In a study funded by the US Food and Drug Administration (FDA), a 2-pronged, model-based approach was recently developed using literature data to link MPH exposure and clinical response characteristics of multiple MPH ER formulations with the aim of identifying the optimal in vivo drug release properties appropriate for maximizing the clinical benefit in the treatment of ADHD.¹³ Using a similar approach, the objectives of this study were to (1) develop PK and PK/PD models for DR/ER-MPH, (2) compare the model-derived PK profile of DR/ER-MPH with those previously determined for 4 other FDA-approved MPH ER formulations, and (3) determine the effect of dose and evening administration time on modeled clinical benefit.

METHODS

Data Sources

The PK model was developed using data collected from 20 healthy adult volunteers (aged 18–55 y) enrolled in a phase 1 PK study.²⁵ A single evening dose of DR/ER-MPH at 20 or 100 mg was administered at 8:00 PM. Blood samples were drawn for determining plasma MPH concentrations predose and at 2, 4, 6, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 36, and 48 hours post dose. Detailed methods of extraction and analysis have been described in previous publications.²⁵ Data obtained in the fasted state were used for the PK model, and individual body weights and sex were explored as potential covariates.

The PK/PD model was developed using Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) composite scores over 9 sampling times from a phase 3 analog classroom study (NCT02493777) of DR/ER-MPH ($n = 64$) versus placebo ($n = 53$) in children (aged 6–12 y) with ADHD.²² The trial consisted of a screening period of 4 weeks or less; a 6-week, open-label, treatment optimization phase to determine the optimal daily dosage and administration time, defined as those that produced meaningful symptom control; and a 1-week, double-blind, placebo-controlled, analog classroom test phase. The SKAMP

combined scores measured from 8:00 AM to 8:00 PM on the classroom test day after a week of double-blind, once-daily treatment with DR/ER-MPH (optimal dose and time) or placebo were used in the PK/PD model.¹³ The SKAMP is a validated rating scale that measures hour-by-hour changes in impaired classroom-observed behaviors and is a widely used measure of efficacy in trials of ADHD. For the purposes of PK/PD modeling, SKAMP can be used for correlating efficacy with PK data.^{13,26} The SKAMP combined score is the sum of scores for all 13 items, in which each item is rated from 0 (no impairment) to 6 (maximum impairment); therefore, SKAMP combined scores range from 0 to 78, with a higher score indicating greater impairment.

PK Model Development

An initial evaluation of the DR/ER-MPH PK data indicated that the concentration-time profile exhibits a time-varying absorption with a disposition and elimination shape consistent with a 1-compartment PK model. Accordingly, the following base reference model was developed:

$$\frac{dC_p}{dt} = f(t) - kel \cdot C_p \quad (\text{Eq. 1})$$

$$f(t) = \frac{dr}{dt} \quad (\text{Eq. 2})$$

where $f(t)$ is the time-varying in vivo release rate and C_p is the MPH concentration.

A convolution-based modeling approach was applied using a prescribed input function with 2 alternative time-varying in vivo absorption models (ie, single and double Weibull functions)¹³:

$$r1(t) = e^{-\left(\left(\frac{\text{time}}{td}\right)^{ss}\right)} \quad (\text{Eq. 3})$$

$$r2(t) = ff \cdot e^{-\left(\left(\frac{\text{time}}{td}\right)^{ss}\right)} + (1-ff) \cdot e^{-\left(\left(\frac{\text{time}}{td}\right)^{ss1}\right)} \quad (\text{Eq. 4})$$

where $r(t)$ is the input function, ff is the fraction of the dose released in the first process, td is the time necessary to deliver 63.2% of the dose in the first process, $td1$ is the time necessary to deliver 63.2% of the dose in the second process, ss is the sigmoidicity factor (ie, a parameter that determines the shape of a sigmoidal curve) for the first process, and $ss1$ is the sigmoidicity factor for the second process. Convolution describes a general modeling approach where 2 functions are combined to generate a third function—in this case, creating a function to determine the concentration-time profile of a drug from functions describing the in vivo input (absorption rate) and elimination time course.

Using a nonlinear mixed effect modeling approach with a first-order conditional estimation with interaction, which allows for an interaction between interindividual variability and residual error. The following parameters were estimated: elimination rate constant (kel), apparent volume of distribution (V_d/F), $r(t)$, interindividual variability, interoccasion variability (IOV), and residual error. Interindividual variability was assumed to be log-normally distributed. Interoccasion variability was determined using an exponential error model because 2 doses (20 or 100 mg) were randomly administered to each participant in a separate treatment period (ie, occasion). Interoccasion variability was not determined for kel because there are no available data indicating potential intraindividual changes in the MPH elimination rate. Residual variability was modeled using a combination of additive and proportional error models.

The performance of alternative absorption models was compared using the log-likelihood ratio test, a statistical test to compare the ability of an alternative model to describe the data. Stepwise forward inclusion and backward elimination processes were applied to assess the impact of prospectively identified covariates, weight and sex, on model parameters. Using the log-likelihood ratio test, the significance levels for the forward addition and backward elimination processes were .05 (objective function value [OFV] ≥ 3.84) and .01 (OFV ≥ 6.63), respectively.

Goodness-of-fit plots were generated for base reference and final models, and coefficients of determination (R^2) were calculated to evaluate the results of model fitting. Visual predictive check (VPC) plots, showing observed data and model-based simulated data, were generated to evaluate the predictive performances of the model. The model-based PK curves of DR/ER-MPH at 20 and 100 mg were then compared with those previously determined for other MPH ER formulations (ie, osmotic release oral system MPH [OROS MPH; Concerta, Janssen Pharmaceuticals, Inc, Titusville, New Jersey], MPH controlled-release delivery [MPH CD; Metadate CD, UCB, Inc, Smyrna, Georgia], MPH ER oral suspension [MEROS; Quillivant XR, Tris Pharma, Inc, Monmouth Junction, New Jersey], and extended-release dexmethylphenidate [d-MPH ER; Focalin XR, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey]) using a similar population PK modeling approach.¹³ Comparisons were conducted assuming that DR/ER-MPH was administered in the evening 10 hours before the MPH ER formulations were administered in the early morning.

PK/PD Model Development

A PK/PD modeling approach generalized on a model previously proposed was applied.^{12,13} Individual MPH exposures from the pediatric PD study were estimated by using the abovementioned population PK model with individual demographic data (ie, weight and sex) and DR/ER-MPH dosing histories.

An indirect response model was used to describe the trajectories of SKAMP scores for placebo:

$$\frac{dR}{dt} = k_{in} \cdot (1 + AA \cdot e^{-t \cdot P_1}) - k_{out} R \quad (\text{Eq. 6})$$

where k_{in} is the zero-order rate constant for the placebo response (R), k_{out} is the first-order rate constant for the loss of response, AA is the amplitude of the placebo effect, and P_1 is the rate of change in the placebo effect. The system was assumed to be stationary (ie, response begins at a baseline value [Bas] that changes with time and returns to Bas); therefore, $k_{in} = \text{Bas} \cdot k_{out}$.

The SKAMP scores of participants treated with DR/ER-MPH were analyzed using the mean individual exposure estimated from population PK parameters, with individual value adjustments to V_d/F and td based on the individual demographic (weight and sex) covariate values. The effect of DR/ER-MPH was described by a change from placebo in SKAMP scores using an E_{max} model:

$$\text{SKAMP}(t) = R(t) \cdot \left(1 - \frac{E_{max} \cdot C_p^g}{EC_{50}^g + C_p^g} \right) \quad (\text{Eq. 7})$$

where E_{max} is the maximal achievable effect, EC_{50} is the MPH concentration associated with half maximal response, C_p is the MPH concentration, and g is the shape of the exposure-response relationship.

The percent change from placebo was defined by

$$\text{Change from placebo (\%)} = \frac{E_{max} \cdot C_p^g}{EC_{50}^g + C_p^g} \quad (\text{Eq. 8})$$

Nonlinear mixed effects modeling was used to describe the exposure-response relationship of DR/ER-MPH, specifically between MPH concentrations and SKAMP scores. Visual predictive check plots were generated to evaluate the predictive performance of the exposure-response model for females and males, and Pearson correlation coefficients were calculated.

Body weight, sex, and age were prospectively identified as covariates of interest. Additional PK/PD models were tested and compared with the base reference model by statistical evaluation of changes in the OFV using log-likelihood ratio test. Visual predictive check plots were generated to evaluate the predictive performance of the PK/PD model.

Estimate of Modeled Clinical Benefit of DR/ER-MPH by Dose and Administration Time

The area under the effect curve computed using the change from placebo in SKAMP scores estimated over a 12-hour period (8:00 AM to 8:00 PM) approximates the duration and magnitude of modeled clinical benefit of DR/ER-MPH treatment compared with placebo. Simulations were conducted using the PK/PD model to estimate the (1) impact of different in vivo release rates (td from 8 to 16 hours; ss from 4.5 to 8.5) and dosing times (4–14 hours before the start of the morning classroom session at 8:00 AM) on the expected clinical benefit and (2) clinical response (trajectories of SKAMP scores) of DR/ER-MPH at doses of 60, 80, and 100 mg simulated in a subject of average weight (34 kg), with the td parameter value fixed to 12.05 hours, the average value of males and females.

Population PK and PK/PD modeling and simulations were conducted using the NONMEM software (version 7.3; ICON Development Solutions, Dublin, Ireland).

RESULTS

PK Model for DR/ER-MPH

A total of 960 plasma MPH concentration measurements were available from healthy adult participants, 14 women and 6 men, for PK model development; demographic data are presented in Supplemental Table 1, <http://links.lww.com/JCP/A674>. The best performing PK model was a 1-compartment model with a first-order k_{el} and an absorption process described by a single Weibull function. The Weibull function is a flexible model particularly useful for characterizing delayed and time-varying absorption processes. Presence of IOV parameters in the model significantly improved its performance ($P < 0.0001$), and covariate analysis revealed that the best performing model included the effect of body weight on V_d/F using an allometric scaling model (ie, weight normalized against a standard weight of 70 kg) and sex on the time necessary to deliver 63.2% of the dose in the first release process (td) (Supplemental Table 2, <http://links.lww.com/JCP/A674>): V_d/F increased with body weight, and td was approximately 20% longer in females versus males (Fig. S1, <http://links.lww.com/JCP/A674>). The sex effect was likely driven by mean body weight, which was lower in females (63.4 kg) than in males (77.5 kg).

Figure S2, <http://links.lww.com/JCP/A674> provides residual diagnostics and goodness-of-fit plots. The VPC plots (Fig. 1) confirm the adequacy of model predictions, demonstrating no apparent deviations between the model and observed data, with individual




FIGURE 1. Median predicted and median observed MPH concentration-time curves after a single evening dose of 20 and 100 mg of DR/ER-MPH in adults. The red solid lines represent the model-predicted median concentrations, and the blue solid lines represent the median observed concentrations. The shaded gray area represents the 90% prediction interval, and the orange dots represent the raw data.

data points symmetrically distributed around the model-predicted median. Corroborating previous studies,^{20,25} DR/ER-MPH exhibited a monophasic PK profile characterized by an initial delay in MPH release, followed by a rapid increase in plasma MPH concentrations, resulting in a smooth ascending plasma concentration profile. After the peak concentration was achieved, there was a slow decline in plasma MPH concentration.

The final population PK parameters are presented in Table 1. The time necessary to release 63.2% of MPH in a single dose was 10.9 hours for males and 13.2 hours for females. The apparent volume of distribution was at least 2-fold greater for DR/ER-MPH than those previously established for other MPH ER formulations (4000 vs 1520 L for OROS MPH, 1920 L for MPH CD, 1960 L for MEROS, and 380 L for d-MPH ER), whereas the k_{el} was generally comparable (0.11 vs 0.18 h^{-1} for OROS MPH, 0.15 h^{-1} for MPH CD, 0.14 h^{-1} for MEROS, and 0.29 h^{-1} for d-MPH ER).¹³ The time-varying absorption rate of DR/ER-MPH was best described by a single rather than double Weibull function that best describes the *in vivo* release of MPH from OROS MPH, MPH CD, MEROS, and d-MPH ER.¹³

Given that 3 of the 4 MPH ER formulations exhibit a biphasic PK profile, as reflected in the visual inspection of simulated PK profiles (Fig. 2), it is difficult to directly compare the parameter estimates of their final PK models to those of DR/ER-MPH. Nevertheless, the slope of the ascending release profile of DR/ER-MPH seems to be not as sharp as other MPH ER formulations, and the elimination phase seems to be protracted. Moreover, DR/ER-MPH allows for the adjustment of evening administration time to target MPH absorption in the early morning. As shown in Figure 2, the timing of evening dosing is important to achieve ascending plasma MPH levels in the early morning. Evening dosing of administration of DR/ER-MPH taken 10 hours prior allows for ascending MPH plasma levels to be achieved before time = 0, the time at which individuals would be taking their morning-administered MPH ER.

PK/PD Model for DR/ER-MPH

The PK/PD model was developed with efficacy data collected from a study of children with ADHD: a total of 557 SKAMP measurements were available from 64 participants treated with DR/ER-MPH; and 470 SKAMP measurements were available from 53 participants treated with placebo. Demographic data are presented in Supplemental Table 1, <http://links.lww.com/JCP/A674>. No differences were detected in demographic data among treatments using χ^2 tests for categorical data and t tests for continuous data. The final mean (SD) optimized dose of DR/ER-MPH was 66.2 (19.56) mg. The placebo model adequately described the shape of SKAMP score trajectories in participants treated with placebo, and the final PK/PD model provided a reasonable estimate of DR/ER-MPH effect. Moreover, the exposure-response relationship adequately described SKAMP response for MPH concentrations after DR/ER-MPH administration (Fig. S3, <http://links.lww.com/JCP/A674>). Covariate analysis revealed that the best performing model was one that included the effect of sex on the half maximal effective concentration (EC_{50}), where EC_{50} was approximately 2-fold higher in males versus females ($P = 0.0005$) (Table 2; see Supplemental Table 3 and Fig. S4, <http://links.lww.com/JCP/A674>). Goodness-of-fit plots for the final population PK/PD model for DR/ER-MPH are provided in Figure S5, <http://links.lww.com/JCP/A674>; VPC plots confirmed the predictive performance of the model (Fig. S6, <http://links.lww.com/JCP/A674>). The estimated parameters of the PK/PD model are presented in Table 2. The simulated exposure-response (percent change from placebo) relationship for DR/ER-MPH revealed that a plasma MPH concentration of approximately 15 ng/mL was necessary to induce an expected maximal improvement in clinical response of approximately 40%, with the fastest rate of change in the exposure-response relationship occurring at concentrations less than 10 ng/mL (Fig. 3).

TABLE 1. Final Population PK Model Parameter Estimates for DR/ER-MPH

Parameter	Estimated Value	SE	RSE, %	CV, %
Fixed effects ^a				
<i>td</i> in males, h	10.90	0.34	3.10	NA
<i>td</i> of females, h	13.20	0.39	3.00	NA
<i>V_d/F</i> , L	4000.00	280.00	7.00	NA
<i>ss</i>	7.52	0.39	5.20	NA
<i>kel</i> , ^b h ⁻¹	0.11	0.01	6.10	NA
Interindividual variability				
<i>td</i> , h	0.005	0.0026	55.50	6.86
<i>V_d/F</i> , L	0.094	0.0281	29.90	30.66
<i>ss</i>	0.040	0.0240	60.30	19.95
<i>kel</i> , h ⁻¹	0.067	0.0185	27.70	25.83
Interoccasion variability				
<i>td</i> , h	0.009	0.0032	35.00	9.59
<i>V_d/F</i> , L	0.008	0.0039	46.50	9.17
<i>ss</i>	0.016	0.0085	51.90	12.77
<i>kel</i> , ^c h ⁻¹	NA	NA	NA	NA
Residual variability				
Additive error	0.04	0.01	22.30	NA
Proportional error	0.17	0.02	10.00	NA

For interindividual variability and interoccasion variability, estimated values indicate variances of the indicated parameters.

^a Mean population parameter values.

^b The derived mean value for the elimination half-life is 6.3 hours.

^c Assumed that *kel* did not change from one occasion to another.

Abbreviations: CV, coefficient of variation; *kel*, elimination rate constant; NA, not available; RSE, relative standard error; SE, standard error; *ss* is the sigmoidicity factor (ie, a parameter that determines the shape of a sigmoidal curve) for the first process; *td* is the time necessary to deliver 63.2% of the dose in the first process; *V_d/F*, apparent volume of distribution.

Modeled Clinical Benefit of DR/ER-MPH by Dose and Administration Time

The modeled clinical benefit of DR/ER-MPH in a laboratory classroom setting was strongly dependent on evening dosing time, with the optimal dosing time estimated at 12 hours before morning classroom start (predicted area under the effect curve after an 80-mg dose: 196 at 12 hours post dose vs 193 at 10 hours, 173 at 8 hours, 167 at 14 hours, 143 at 6 hours, and 111 at 4 hours). For 60- and 100-mg doses, the optimal dosing time was also estimated at 12 hours before the morning classroom start.

Simulations of clinical response using SKAMP score trajectories at 60, 80, and 100 mg of DR/ER-MPH indicated that higher doses provide an extended duration of clinical response that occur slightly earlier in the morning (starting approximately 10 hours post dose with 60 mg), remain constant throughout the day, and last longer into the evening (Fig. 4). The model showed that, with increasing doses, the predicted duration of SKAMP response versus placebo was extended without affecting the maximal difference between DR/ER-MPH and placebo responses during the day.

DISCUSSION

Using model-based approaches, we linked the in vivo release properties of DR/ER-MPH with its hourly exposure-response relationship and established its clinical response throughout the day. The main findings were that DR/ER-MPH (1) is characterized by a 1-compartment PK model with a time-varying in vivo release rate best described by a single Weibull function, distinct from the model that describes other ER MPH; (2) demonstrates a clinical response profile with clinical benefit predicted to start at approximately

10 hours post administration, a time corresponding to the early morning, and last into the evening, consistent with clinical trial data^{21,22}; and (3) has a dose-dependent duration of effect.

The 1-compartment PK model of DR/ER-MPH with the time-varying in vivo release rate characterized by a single Weibull function reflects the delayed-release and extended-release monophasic PK profile previously demonstrated in 5 single-dose PK studies of DR/ER-MPH in healthy adults and youth with ADHD.^{20,25} In 2 of these single-dose studies, evening administration of a single 54-mg DR/ER-MPH dose resulted in similar weight-adjusted PK profiles when administered to healthy adults compared with children and adolescents with ADHD, indicating that a population PK model derived from adult PK data with weight as a covariate would be applicable to modeling the PK/PD relationship in children with ADHD. Data from a single PK study in healthy adults were used to develop the population PK model because it was the only PK study in which multiple doses (20 and 100 mg) were administered to the same individuals under the same conditions, which allowed estimation of IOV.

A recent modeling study of FDA-approved MPH ER products demonstrated that these formulations are also characterized by a 1-compartment PK model; however, the in vivo MPH release rates were found to be best defined by a double Weibull function,¹³ which is generally consistent with the dual release properties of MPH ER formulations, as each of the studied MPH ER products has immediate-release and extended-release components.^{11,13} These differences in PK models suggest that in vivo drug release from DR/ER-MPH may function more like an infusion with a single release process, congruent with its single-bead composition, rather than a formulation that has 2 separate release processes.




FIGURE 2. Comparison of mean MPH concentration (conc) time curves of single evening doses of DR/ER-MPH (20 and 100 mg) and single morning doses of OROS MPH (18, 36, and 54 mg), MPH CD (20, 40, and 60 mg), d-MPH ER (20 mg), and MEROS (60 mg). Evening-dosed DR/ER-MPH is assumed to be administered 10 hours before morning administration.

Because of the differing Weibull functions describing *in vivo* release, it is difficult to compare PK parameters derived from the respective models. Nonetheless, visual comparisons of the PK curves modeled for DR/ER-MPH versus other MPH ER formulations confirmed that DR/ER-MPH produces a monophasic PK profile with an initial delay in MPH release and a subsequent period of extended, controlled release. Importantly, the flexible evening administration of DR/ER-MPH allows for therapeutic MPH levels to be achieved upon awakening through individualized dosing time adjustments between 6:30 and 9:30 PM. After reaching peak concentrations, the elimination phase of the PK profile is

protracted for DR/ER-MPH versus other MPH ER formulations. Owing to its delayed-release properties, DR/ER-MPH has a longer transit through the gastrointestinal tract without any release of MPH, likely resulting in targeted delivery of MPH to the less absorptive colon.²⁰ Indeed, it was found that the V_d/F was at least 2-fold greater for DR/ER-MPH versus other MPH ER formulations. This result can be explained by 2 effects resulting from targeting MPH release and absorption at the colon: (1) DR/ER-MPH exhibits an extended elimination half-life, which is positively correlated with V_d compared with other ER MPH, and (2) DR/ER-MPH demonstrates lower bioavailability (F) (~75% relative bioavailability to IR MPH)²⁵ compared with other ER MPH (comparable relative bioavailability to IR MPH).^{27,28} The reduced relative bioavailability of DR/ER-MPH compared with IR MPH was hypothesized to result from a fraction of MPH undergoing fecal elimination due to incomplete colonic absorption.²⁵

The PK/PD model developed for DR/ER-MPH provided a reasonable estimate of its exposure-response relationship and predicted clinical response across varying doses. The best performing model includes sex as a covariate on EC_{50} , with males having a 2-fold higher EC_{50} . This suggests that females may have a higher sensitivity to DR/ER-MPH with respect to clinical response, although further research is warranted to prospectively test this simulated finding.

The simulated exposure-response relationship estimated that a plasma MPH concentration of approximately 15 ng/mL induces a maximal improvement in clinical response of 40%, with the fastest rate of change in the exposure-response relationship achieved with concentrations less than 10 ng/mL. Although most study participants were not predicted to reach 15 ng/mL, it is important to note that therapeutic response to MPH is associated with the rate of rise in plasma concentrations in addition to the extent of drug absorption or attainment of an ultimate concentration responsible for the maximal clinical response.⁸ Furthermore, imaging studies have suggested that maximal dopamine transporter (DAT) occupancy is achieved at plasma MPH concentrations of approximately 10 ng/mL.²⁹ Given that DAT occupancy is a key driver of clinical efficacy, the plateauing of the simulated clinical response between 10 and 15 ng/mL may be related to reaching maximal DAT occupancy; however, this is purely speculative, and the real-world implications on clinical practice are unknown.

The modeled clinical benefit of DR/ER-MPH was found to be strongly dependent on evening dosing time, with the optimal dosing time estimated to be 12 hours before the classroom start at 8:00 AM. This is consistent with the most common prescribed dosing time of 8:00 PM reported in 2 pivotal phase 3 trials of DR/ER-MPH.^{21,22} In addition, the modeling approach enabled us to establish a dose-response relationship of DR/ER-MPH using efficacy data derived from the double-blind portion of a phase 3 trial, during which children were at an optimized dose and administration time. Simulations of the predicted clinical response at doses of 60, 80, and 100 mg of DR/ER-MPH revealed a dose-dependent duration of effect, with higher doses extending the duration of clinical response without affecting the magnitude of clinical benefit during the day. Given that the simulated clinical response of DR/ER-MPH is dependent on both the timing of evening administration and dosage strength, treatment may be individualized or optimized based on patient needs and tolerability. In the pediatric PD study, the optimized dose of DR/ER-MPH after a 6-week, open-label, treatment optimization phase was approximately 65 mg,²² which reflects clinicians' judgment in balancing efficacy and tolerability for individual children.

Kimko and colleagues¹² were the first to develop a PK/PD model for MPH ER formulations. Despite the absence of a formal model describing the multimodal MPH PK profile and a

TABLE 2. Final PK/PD Model Parameter Estimates for DR/ER-MPH

Parameter	Estimated Value	SE	RSE, %	CV, %
Fixed effects ^a				
EC ₅₀ in males, ng/mL	8.400	0.572	6.80	NA
EC ₅₀ in females, ng/mL	3.720	0.536	14.40	NA
E _{max}	0.402	0.035	8.70	NA
g ^b	12.600	6.260	49.70	NA
Interindividual variability				
EC ₅₀ , ng/mL	0.0712	0.0218	30.60	26.68
E _{max}	0.0437	0.0188	43.00	20.90
Residual variability				
Additive error	2.270	0.350	15.40	NA
Proportional error	0.298	0.031	10.30	NA

For interindividual variability, estimated values indicate variances of the indicated parameters.

- ^a Mean population parameter values.
^b In this analysis, it was not possible to estimate the random effect for the g parameter.

Abbreviations: CV, coefficient of variation; EC₅₀, half maximal effective concentration; E_{max}, maximum effect; g, shape of the exposure-response relationship; RSE, relative standard error; SE, standard error.

continuous function to characterize the time course of placebo SKAMP scores,¹³ the modeling approach used by Kimko and colleagues¹² allowed them to characterize the change from placebo in SKAMP scores in children with ADHD as a function of MPH concentrations derived from PK studies in healthy adults. In addition to establishing that a convolution-based modeling approach most accurately describes the dual release process and complex PK profiles of different MPH ER formulations, Gomeni and colleagues¹³ previously built upon the initial PK/PD model proposed by Kimko and colleagues¹² by linking the time courses of the multimodal in vivo and in vitro release properties with hourly changes in SKAMP to provide a framework for estimating and optimizing the clinical benefit of MPH ER treatments. Although a similar modeling approach was used in this study, the findings need to be considered in light of some limitations. First, like the previous modeling studies of MPH ER,^{12,13} PK data were obtained from healthy adult volunteers and PD data were obtained from children with ADHD, and therefore, predicted rather than actual concentrations were used in the PK/PD model for DR/ER-MPH. A previous

study reported similar body-weight-adjusted PK properties of DR/ER-MPH in healthy adults and children with ADHD²⁰; however, it is possible that differences may remain between actual MPH concentrations from the pediatric efficacy study and the predicted concentrations based on the population PK model based on healthy adult data. Therefore, the findings from this study would benefit from confirmation in a future study where PK and efficacy measurements were both included. Another limitation of this study is that modeled clinical benefit was determined based solely on reduction of impairment based on classroom behaviors, as measured by SKAMP, and did not include data on functional impairment outside the classroom or tolerability; however, time-dependent PK/PD modeling is not possible for nonclassroom outcomes because SKAMP is the only scale measuring hourly changes in ADHD symptoms and behaviors that allows for correlation with PK data.^{12,13} Although the simulations predict a clinical benefit starting approximately 10 hours post dose (Fig. 4), corresponding to the early morning for children in the PD trial, it is difficult to interpret how this prediction of clinical benefit based on




FIGURE 3. Relationship between MPH exposure and predicted clinical response for DR/ER-MPH. Clinical response was defined as a change in simulated SKAMP scores from placebo. The solid line represents the simulated response, and the shaded area represents the 90% prediction interval.




FIGURE 4. Predicted clinical response of DR/ER-MPH at varying doses (60, 80, and 100 mg) versus placebo. Clinical response was represented by the simulated SKAMP composite score trajectories.

classroom behaviors would apply to nonclassroom settings in the early morning. However, the model-predicted early morning benefit is consistent with a significant improvement with DR/ER-MPH versus placebo in early morning functional impairment, as measured by the morning subscale of the Parent Rating of Evening and Morning Behavior, Revised in the PD trial.²² A final limitation is that clinical data used in the modeling were obtained using optimized doses of DR/ER-MPH, where optimal dosage was defined as dose and administration time producing meaningful symptom control while remaining well tolerated. Despite these limitations, supporting evidence for the flexibility of this modeling framework has been demonstrated in other recent studies,¹³ and the proposed modeling methodology can provide a useful tool for individualizing therapy in patients with ADHD.

In conclusion, using a model-based approach, the PK of DR/ER-MPH was found to be best characterized by a 1-compartment PK model with the time-varying absorption rate described by a single Weibull in vivo release function, and the PK/PD model developed for DR/ER-MPH provided a reasonable estimate of its clinical response. The maximum clinical benefit was predicted with evening dosing 12 hours before the start of the classroom day. In addition, DR/ER-MPH has a dose-dependent duration, with higher doses resulting in modeled clinical benefit lasting longer into the evening. Given that the estimated mean clinical response of DR/ER-MPH was dependent on the dose strength and timing of evening administration, treatment may be individualized based on patient needs. As with any PK/PD modeling approach, confirmation of these findings is warranted via prospective clinical trials.

ACKNOWLEDGMENT

The authors thank the patients, their families, and the clinical teams who worked on the studies that yielded the data necessary for the modeling and analyses presented herein. Under the direction of the authors, medical writing support was provided by Michelle D. Po, PhD (Highland Therapeutics Inc).

AUTHOR DISCLOSURE INFORMATION

R.G., M.K., B.I., and S.V.F. wrote the article; R.G., M.K., B.I., and S.V.F. designed the research; R.G. and B.I. performed the research; and R.G. analyzed the data.

Roberto Gomeni, PhD, is a paid consultant to Ironshore Pharmaceuticals & Development, Inc; Sunovion Pharmaceuticals Inc; Supernus Pharmaceuticals, Inc; Teva Branded Pharmaceutical Products R&D, Inc; Biomedical Science Institutes, Singapore; Nanomi BV, The Netherlands; Laboratorios Liconsa S.A., Spain; General Hospital Corporation, Boston, Massachusetts; and UCB

Biopharma SPRL. Marina Komolova, PhD, is an employee of Highland Therapeutics Inc. Bev Incledon, PhD, is an employee of Ironshore Pharmaceuticals & Development, Inc. Stephen V. Faraone, PhD, received income, potential income, travel expenses, continuing education support, and/or research support from Tris, Otsuka, Arbor, Ironshore, Shire, Akili Interactive Labs, Enzymotec, Sunovion, Supernus, and Genomind. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of attention-deficit/hyperactivity disorder. He also receives royalties from books published by Guilford Press, Straight Talk about Your Child's Mental Health; Oxford University Press, Schizophrenia: The Facts; and Elsevier, ADHD: Non-Pharmacologic Interventions. He is Program Director of www.adhdinadults.com.

This work was supported by Ironshore Pharmaceuticals & Development, Inc.

REFERENCES

1. Faraone SV, Asherson P, Banaschewski T, et al. Attention-deficit/hyperactivity disorder. *Nat Rev Dis Prim.* 2015;1:15020.
2. Xu G, Strathearn L, Liu B, et al. Twenty-year trends in diagnosed attention-deficit/hyperactivity disorder among US children and adolescents, 1997–2016. *JAMA Netw Open.* 2018;1:e181471.
3. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. *Psychol Med.* 2006;36:159–165.
4. Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry.* 2007;46:894–921.
5. Wolraich ML, Hagan JF, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. *Pediatrics.* 2019;144:e20192528.
6. Childress AC. Methylphenidate HCL for the treatment of ADHD in children and adolescents. *Expert Opin Pharmacother.* 2016;17:1171–1178.
7. Faraone SV. The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. *Neurosci Biobehav Rev.* 2018;87:255–270.
8. Swanson J, Gupta S, Guinta D, et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. *Clin Pharmacol Ther.* 1999;66:295–305.
9. Volkow ND, Fowler JS, Wang G, et al. Mechanism of action of methylphenidate: insights from PET imaging studies. *J Atten Disord.* 2002;6:S31–S43.

10. Frölich J, Banaschewski T, Döpfner M, et al. An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/hyperactivity disorder. *Expert Opin Drug Metab Toxicol*. 2014;10:1169–1183.
11. Maldonado R. Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate. *Expert Opin Drug Metab Toxicol*. 2013;9:1001–1014.
12. Kimko H, Gibiansky E, Gibiansky L, et al. Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis. *J Pharmacokinet Pharmacodyn*. 2012;39:161–176.
13. Gomeni R, Bressolle-Gomeni F, Spencer TJ, et al. Model-based approach for optimizing study design and clinical drug performances of extended-release formulations of methylphenidate for the treatment of ADHD. *Clin Pharmacol Ther*. 2017;102:951–960.
14. Birmaher B, Greenhill LL, Cooper TB, et al. Sustained release methylphenidate: pharmacokinetic studies in ADHD males. *J Am Acad Child Adolesc Psychiatry*. 1989;28:768–772.
15. Hubbard JW, Srinivas NR, Quinn D, et al. Enantioselective aspects of the disposition of dl-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder. *J Pharm Sci*. 1989;78:944–947.
16. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. *Arch Gen Psychiatry*. 2003;60:204–211.
17. Wigal SB, Wigal T, Childress A, et al. The time course of effect of multilayer-release methylphenidate hydrochloride capsules. *J Atten Disord*. 2020;24:373–383.
18. Sallee FR. Early morning functioning in stimulant-treated children and adolescents with attention-deficit/hyperactivity disorder, and its impact on caregivers. *J Child Adolesc Psychopharmacol*. 2015;25:558–565.
19. Faraone SV, Schachar RJ, Barkley RA, et al. Early morning functional impairments in stimulant-treated children with attention-deficit/hyperactivity disorder versus controls: impact on the family. *J Child Adolesc Psychopharmacol*. 2017;27:715–722.
20. Childress A, Mehrotra S, Gobburu J, et al. Single-dose pharmacokinetics of HLD200, a delayed-release and extended-release methylphenidate formulation, in healthy adults and in adolescents and children with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol*. 2018;28:10–18.
21. Pliszka SR, Wilens TE, Bostrom S, et al. Efficacy and safety of HLD200, delayed-release and extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol*. 2017;27:474–482.
22. Childress AC, Cutler AJ, Marraffino A, et al. A randomized, double-blind, placebo-controlled study of HLD200, a delayed-release and extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder: an evaluation of safety and efficacy throughout the day and across settings. *J Child Adolesc Psychopharmacol*. 2020;30:2–14.
23. US Department of Health and Human Services Food and Drug Administration. Physiologically based pharmacokinetic analyses—format and content guidance for industry. Available at : <https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>. Accessed February 4, 2020.
24. Gomeni R, Bressolle-Gomeni F, Fava M. Response surface analysis and nonlinear optimization algorithm for maximization of clinical drug performance: application to extended-release and long-acting injectable paliperidone. *J Clin Pharmacol*. 2016;56:1296–1306.
25. Liu T, Gobburu J, Po MD, et al. Pharmacokinetics of HLD200, a delayed-release and extended-release methylphenidate: evaluation of dose proportionality, food effect, multiple-dose modeling, and comparative bioavailability with immediate-release methylphenidate in healthy adults. *J Child Adolesc Psychopharmacol*. 2019;29:1–11.
26. Wigal SB, Gupta S, Guinta D, et al. Reliability and validity of the SKAMP rating scale in a laboratory school setting. *Psychopharmacol Bull*. 1998;34:47–53.
27. Modi NB, Lindemulder B, Gupta SK. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. *J Clin Pharmacol*. 2000;40:379–388.
28. Childress AC, Berry SA. The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. *Postgrad Med*. 2010;122:35–41.
29. Volkow ND, Wang G-J, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. *Am J Psychiatry*. 1998;155:1325–1331.